Perspectives on Recent Advances in Alzheimer Disease
A panel discusses the latest progress in treatment, current diagnostic processes, and various therapies that have advanced through the pipeline.
An Overview of Therapeutic Options for Amyotrophic Lateral Sclerosis
With an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
EMERGE Study Aims to Highlight Therapeutic Benefit of AXS-07 After CGRPs Fail
Now 4 years after the approvals of the first calcitonin gene-related peptide inhibitors, new therapies are being developed to address the lingering needs of patients with refractory migraine.
Activation of NRF2 and FXN in Friedreich Ataxia
Disease pathogenesis is attributed to oxidative stress—which can be regulated by NRF2, which, in turn, binds to antioxidant responsive elements in the promoter of the target gene FXN to control its expression.
Bruton Tyrosine Kinase Inhibitors: A New Hope for the Management of Progression in MS?
Several therapies are progressing through the development pipeline and have shown promising data, setting up the multiple sclerosis treatment toolbox for possible expansion in coming years.
Let’s Get Moving: A Multidisciplinary Approach to Gait Rehabilitation in Multiple Sclerosis
Current research pushes to advance therapeutic possibilities and understand underlying neural mechanisms for gait impairments in individuals with the disease.
From “Diagnose and Adiós” to Brain Health: Are We There Yet?
Since the days of limited treatment in neurology, 30 years of progress have brought an expanded armamentarium of therapies for many neurological disorders.
FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease
Marketed as Leqembi, the agent was approved through the accelerated approval pathway and was based on a major study featuring almost 900 patients with early Alzheimer disease.
FDA Designates Myasthenia Gravis Agent Rozanolixizumab Application for Priority Review
UCB’s rozanolixizumab received priority review on its biologic license application by FDA and expects feedback during the second quarter of 2023.
Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple Sclerosis
Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.
Seizure-Free Days and Duration Intervals Increased With Fenfluramine in Dravet Syndrome
In a recent time-to-event analysis based on two clinical trials of patients with Dravet syndrome results demonstrated an overall reduction in seizure burden with fenfluramine.
NeuroVoices: Sube Banerjee, MD, MSc, MBA, FRCPsych, on Replacing Traditional Noneffective Agents for Alzheimer Agitation
The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.
Chronic ASM Use Associated With Acute Symptomatic Seizures in Patients With Stroke
Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.
Cenobamate Not Associated With Clinically Significant Weight Change in Epilepsy Treatment
Notably, though, cenobamate treatment was associated with weight reductions among patients who were categorized as overweight and obese, but not in those who were underweight or normal weight.
XEN1101 Posts Positive Efficacy, Safety in Focal-Onset Epilepsy in Interim Phase 2b Open-Label Data
The investigational therapy from Xenon Pharmaceuticals showed marked reductions in monthly seizure frequency from months 14 to 20, with consistent safety and good retention rates.
Transition to Adult Care Is Inconsistent for Patients With Dravet Syndrome, Survey Suggests
A survey conducted in conjunction with the Dravet Syndrome Foundation suggests that many patients with DS do not undergo the transition of care from pediatric to adult neurology providers, with caregivers of those who did expressing some concerns about the process.
2 Clarke Drive Cranbury, NJ 08512